A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

PHASE3CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Papulopustular Rosacea
Interventions
DRUG

DFD-29

DFD-29 (40 mg) extended release capsules

DRUG

Doxycycline

Doxycycline 40 mg capsules

DRUG

Placebo

Placebo capsules

Trial Locations (27)

10019

Clinical Trial Site 24, New York

18249

Clinical Trial Site 01, Sugarloaf

27262

Clinical Trial Site 17, High Point

28405

Clinical Trial Site 04, Wilmington

33134

Clinical Trial Site 08, Coral Gables

Clinical Trial Site 22, Coral Gables

33761

Clinical Trial Site 11, Clearwater

37215

Clinical Trial Site 23, Nashville

44122

Clinical Trial Site 06, Beachwood

46250

Clinical Trial Site 02, Indianapolis

48088

Clinical Trial Site 28, Warren

48103

Clinical Trial Site 18, Ann Arbor

55112

Clinical Trial Site 21, New Brighton

66210

Clinical Trial Site 27, Overland Park

72758

Clinical Trial Site 05, Rogers

75093

Clinical Trial Site 07, Plano

77055

Clinical Trial Site 13, Houston

77845

Clinical Trial Site 20, College Station

78213

Clinical Trial Site 26, San Antonio

78229

Clinical Trial Site 12, San Antonio

89148

Clinical Trial Site 15, Las Vegas

90703

Clinical Trial Site 10, Cerritos

92123

Clinical Trial Site 25, San Diego

Clinical Trial Site 29, San Diego

94538

Clinical Trial Site 03, Fremont

02135

Clinical Trial Site 09, Brighton

02818

Clinical Trial Site 19, East Greenwich

All Listed Sponsors
collaborator

Dr. Reddy's Laboratories Limited

INDUSTRY

lead

Journey Medical Corporation

INDUSTRY

NCT05296629 - A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. | Biotech Hunter | Biotech Hunter